Product Information
TRI-VYLIBRA 28 TABLET is a generic product labeled by Afaxys Pharma, LLC, priced at $0.1286 per EA under NDC 50102023313. Its NADAC has been published 425 times since May 9, 2018.
Manufacturer
Afaxys Pharma, LLCNDC
50102023313
Classification
Generic
Dosage Form
KIT
Last Updated
6/17/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA205441On Market Since
7/6/2016
Price Statistics
The NADAC for TRI-VYLIBRA 28 TABLET has been published 425 times since May 9, 2018, and over the history we have for it it has declined 45.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1286 per EA |
|---|---|
| All-time high | $0.2397 (Sep 12, 2018) |
| All-time low | $0.1072 (Jul 17, 2024) |
| 52-week high | $0.1375 |
| 52-week low | $0.1286 |
| Median price | $0.1564 |
| Average price | $0.1652 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 425 |
| Tracking since | May 9, 2018 |
Generic Alternatives
The matcher finds 7 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 7 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 18% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of TRI-VYLIBRA 28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-VYLIBRA 28 TABLET, manufactured by Afaxys Pharma, LLC, is $0.1286 per EA (NDC 50102023313), effective Jun 24, 2026.
How has the price of TRI-VYLIBRA 28 TABLET changed over time?
Over the history we have for it, the NADAC for TRI-VYLIBRA 28 TABLET has declined 45.8%. It has been tracked across 425 weekly CMS publications since May 9, 2018.
What are the highest and lowest recorded NADAC prices for TRI-VYLIBRA 28 TABLET?
Since May 9, 2018, the NADAC for TRI-VYLIBRA 28 TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.2397 (Sep 12, 2018), with a median of $0.1564 per EA.
Are there cheaper alternatives to TRI-VYLIBRA 28 TABLET?
Yes. 7 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, TRI-VYLIBRA LO TABLET, is $0.1049 per EA — about 18% below TRI-VYLIBRA 28 TABLET.
Who manufactures TRI-VYLIBRA 28 TABLET?
TRI-VYLIBRA 28 TABLET (NDC 50102023313) is labeled by Afaxys Pharma, LLC, and CMS classifies it as a generic product.
Related Drugs
Same classification